Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

No, this isn’t some late-night infomercial fantasy — it’s the reality of Zepbound, and it’s changing everything about how we approach weight loss. While you’ve been cycling through diets ...

Zepbound is most effective when combined with a balanced diet and regular exercise. Eating plenty of filling and nutrient-dense foods can help you work toward your weight loss goals. Zepbound ...

If you’re living with overweight or obesity and are interested in exploring Zepbound as a treatment option, consulting a healthcare professional for a comprehensive evaluation is crucial.

A microsimulation model published in JAMA Health Forum projected that Medicare expenditures would increase by $47.7 billion over 10 years if drugs such as Wegovy and Zepbound were covered under ...

With other races on the horizon, she decided to go back on tirzepatide, the active ingredient in popular diabetes and weight-loss drugs Mounjaro and Zepbound. She had used it before to take off ...

So did Eli Lilly, which makes the weight-loss drug Zepbound and Mounjaro, a similar drug tailored to diabetes patients. Together, the two companies hired more than 10 lobbying firms, including top ...